Fisher Scientific
This article was originally published in The Gray Sheet
Executive Summary
Life-sciences and biochemicals segments are bolstered through acquisition of Oxoid Group Holdings for $330 mil. and Dharmacon for $80 mil. under separate definitive agreements. Oxoid adds $155 mil. in revenue from microbiological culture media and other products to test for bacterial contamination, used in research labs, drug production and process validation. Dharmacon, with sales of $17 mil., provides RNA-based products for life science research and drug discovery. "We anticipate sales of higher-margin, proprietary products to increase from 45% to approximately 50% of total sales as a result of these acquisitions," Fisher says...